Region — US. Neutral scientific reference — not offered for sale here.
Explore /
CJC-1295 + Ipamorelin ("CJC/Ipa") Research reference — not for sale
CJC-1295 + Ipamorelin ("CJC/Ipa")
Blend / combination⚠ WADA-banned
also called — "CJC/Ipa" · "GHRH + GHRP stack" · GH-secretagogue combination. INCI: none
Research / reference — not for sale. No dosing, reconstitution, or administration is published (intentional). A combination, not a single molecule — and the most-marketed GH-peptide stack with the least combination-specific evidence.
Legal standing, by region
the status of both components applies — placed in 503A Category 2 (2023), status in flux in 2026, not among the July 23–24 2026 PCAC seven, not FDA-approved; not approved in the EU; WADA-prohibited (S2.2).
⚠ WADA-prohibited in sportWADA-prohibited (S2
Evidence, by outcome
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Synergistic GH release (combination)
Mechanistically sound, but see below — the specific combo is essentially untested in controlled trials
Mechanistic (GHRH + GHRP synergy is established); each component raises GH in humans · Larger GH pulse than either alone (plausible)
CThe specific CJC-1295 + Ipamorelin combination for any clinical endpoint
Zero combination RCT; anti-aging/body-composition claims are extrapolation
No controlled clinical trial has evaluated it · Not demonstrated
FSafety (combination)
Inherits both components' unknowns; GH/IGF-1 elevation theoretical risks; WADA-banned
No dedicated human safety data · Unknown
—The honest part
this is the clearest "popularity ≠ evidence" case in the register — the most-marketed GH stack, yet no controlled trial has ever tested the combination. What is known is the pharmacology of each part (they raise GH), not that the stack delivers the outcomes it is sold for.
Identity a combination of two separate peptides — CJC-1295 (a GHRH-receptor agonist, #16) and Ipamorelin (a GHS-R1a / ghrelin-receptor agonist, #17). Not a single compound. ## Rationale the two act through two different receptors — GHRH-R and the ghrelin receptor — and their signals are complementary, producing a greater GH pulse together than either alone (a long-established GHRH + GHRP synergy in endocrine pharmacology). Neither component meaningfully raises cortisol or prolactin, so the combination is relatively "clean" hormonally. It is the most widely used GH-peptide pairing in functional-medicine and gray-market protocols.
Review status
Not yet reviewed
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
Region — United States
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.